department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Torsemide · pharmadog

pharmadog
drugs
Torsemide

drug

patient view →

torsemide

Marketedupdated 2mo ago

by CorePharma LLC

Approved

community read0 votes

indications

investigational

Hypertension

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Torsemide

generic

torsemide

indication

Hepatic Edema

phase

marketed

Data sources

ClinicalTrials.gov

last refreshed 56m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Patent cliff

source: FDA Orange Book

first barrier falls

Oct 6, 2033

~7.3 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (2)

Oct 6, 2033formulationUS 10154963
Oct 6, 2033formulationUS 10154963

Trials studying torsemide

phase1Comparison of Once Daily 40 mg Torsemide With Twice-daily 40 mg Furosemideterminatedn=20
phase2Effect of Extended Release Torsemide in Patients With Congestive Heart Failure and Overactive Bladdercompletedn=24
phase4Comparing Natriuretic Effects of ER Torsemide to IR Torsemide in Patients With Heart Failurecompletedn=20
phase3Bioavailability and Bioequivalence Study of Extended Release Torsemide and Spironolactonecompletedn=24
phase3A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Diseaserecruitingn=30
phase3A Study to Evaluate the Effect of Food or no Food on the Bioavailability of an Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Adult Subjectscompletedn=24
phase3Bioavailability and Bioequivalence Study of ER Torsemide and Spironolactone FDC Tablet in Healthy Subjectscompletedn=24
phase4A Crossover Study of Patients with HF to Compare Natriuretic Effects of IR Torsemide Vs. ER Torsemide Over 12 Hrsterminatedn=5

more trials →